Report #2842522

Overview

Sex

Female

Age

Age unknown

State

MO

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

Administration after a below temperature excursion of 29.9°F as the minimum reached; This non-serious case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a adult female patient who received Herpes zoster (Shingrix) (batch number M7G39) for prophylaxis. Co-suspect products included RSVPreF3 adjuvanted (Arexvy) (batch number 44TR9) and (batch number DL32D) for prophylaxis, DTPa (Reduced antigen) (Boostrix) (batch number 39LB7) and (batch number 2B723) for prophylaxis, Men ACWY-CRM NVS (Menveo) (batch number AMVBO44A) and (batch number LB93L) for prophylaxis, HAV (Havrix) (batch number 423NO) for prophylaxis and Flu Seasonal TIV Dresden (Fluarix) (batch number PG52S) for prophylaxis. On an unknown date, the patient received Shingrix and Arexvy. On an unknown date, the patient received Boostrix. On an unknown date, the patient received Menveo. On an unknown date, the patient received Havrix and Fluarix. On an unknown date, an unknown time after receiving Shingrix, Arexvy, Boostrix, Menveo, Havrix and Fluarix, the patient experienced incorrect storage of drug (Verbatim: Administration after a below temperature excursion of 29.9°F as the minimum reached). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 15-MAY-2025 A registered nurse asked the recommendations after giving several vaccines that were exposed to a below temperature excursion reported in case 02294438 of 29.9 degree Fahrenheit as the lowest reached for following products: Arexvy (lot numbers: 44TR9 and DL32D), Boostrix (39LB7 and 2B723), Menveo (1 vial: AMVBO44A and LB93L), Havrix (423NO), Fluarix (PG52S) & Shingrix (M7G39) which led to incorrect storage of drug. The Vaccine Administration Facility is the same as Primary Reporter. No expiration date was given for the vaccines nor the date of administration. Consented to follow up.; Sender's Comments: US-GSK-US2025061548: US-GSK-US2025061546:Same reporter,Different patient US-GSK-US2025061545: